All News


All series


All All News

The FDA has granted an accelerated approval to larotrectinib for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.

When I was first diagnosed, I searched for the stories that would give me hope in the darkness that surrounded me. Seven years later, I continue to pay it forward by putting my own story out there for the next person who needs it to find.

Health care shouldn't be a fight, but it is. I tell my story of fighting for an MRI in a hope that I illuminate the cracks in our system in a hope we can make change, so no one falls through those cracks.